[{"id":"4811680a-497e-488d-8abd-34a9b22c5b1c","acronym":"TeliMET NSCLC-01","url":"https://clinicaltrials.gov/study/NCT04928846","created_at":"2021-06-16T18:52:53.966Z","updated_at":"2025-02-25T15:35:07.629Z","phase":"Phase 3","brief_title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04928846 - TeliMET NSCLC-01","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Recruiting","enrollment":" Enrollment 698","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-10"},{"id":"0709de84-6a21-4b70-87e0-b0abfb01cd20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05513703","created_at":"2022-08-24T21:07:39.445Z","updated_at":"2024-07-02T16:35:09.671Z","phase":"Phase 2","brief_title":"A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05513703","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/18/2025","primary_completion_date":" 03/18/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-04-15"},{"id":"30039935-dcb8-4bf7-a489-908bf7235f71","acronym":"LUMINOSITY","url":"https://clinicaltrials.gov/study/NCT03539536","created_at":"2021-01-18T17:26:22.732Z","updated_at":"2024-07-02T16:35:22.832Z","phase":"Phase 2","brief_title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03539536 - LUMINOSITY","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • MET overexpression • MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-01-19"},{"id":"4517ce65-ebe5-48ef-b3a0-5e1b03bf3e96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093503","created_at":"2023-10-23T20:13:56.005Z","updated_at":"2024-07-02T16:35:32.453Z","phase":"Phase 3","brief_title":"Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein","source_id_and_acronym":"NCT06093503","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 04/11/2028","primary_completion_date":" 04/11/2028","study_txt":" Completion: 04/11/2028","study_completion_date":" 04/11/2028","last_update_posted":"2023-10-20"},{"id":"88937094-cd92-4d3c-b628-9e0e2ffc12f1","acronym":"M14-237","url":"https://clinicaltrials.gov/study/NCT02099058","created_at":"2021-01-17T17:35:29.259Z","updated_at":"2024-07-02T16:35:42.807Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02099058 - M14-237","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tagrisso (osimertinib) • erlotinib • Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 04/24/2024","primary_completion_date":" 04/24/2024","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2023-07-17"},{"id":"d13c635a-1aa3-4a77-af1d-2a98cdcc79c8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT03574753","created_at":"2021-01-18T17:35:20.794Z","updated_at":"2024-07-02T16:36:22.818Z","phase":"Phase 2","brief_title":"Lung-MAP S1400K: c-MET Positive","source_id_and_acronym":"NCT03574753 - LUNG-MAP SUB-STUDY","lead_sponsor":"Southwest Oncology Group","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 12/21/2019","primary_completion_date":" 12/21/2019","study_txt":" Completion: 07/30/2021","study_completion_date":" 07/30/2021","last_update_posted":"2021-10-18"}]